OpenAI CEO Sam Altman is doubling down on Retro Biosciences, a biotech startup primarily based in San Francisco that desires people to reside 10 years longer than what it calls a wholesome human lifespan.
Altman beforehand offered Retro Biosciences’ complete seed spherical of $180 million. Now, the startup is elevating a $1 billion Collection A that Altman is becoming a member of, the Monetary Instances reviews.
Retro Biosciences, which says it plans to launch trials for medication focusing on ailments like Alzheimer’s, lately skilled a mannequin with OpenAI to show common cells into stem cells.
CEO Joe Betts-LaCroix instructed the FT he desires to maneuver quick by discovering and creating a drug “within the 2020s.”
The startup joins different main billionaire-backed longevity efforts, together with Altos Labs, which launched with $3 billion in 2022 backed by Jeff Bezos, and Unity Biotechnology, supported by each Bezos and Peter Thiel.
